Enting R H, Spanjaard L, van de Beek D, Hensen E F, de Gans J, Dankert J
Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands.
J Antimicrob Chemother. 1996 Nov;38(5):777-86. doi: 10.1093/jac/38.5.777.
The increasing antimicrobial resistance among pathogens frequently isolated from patients with bacterial meningitis formed the rationale to perform a surveillance study to determine the prevalence of resistance in The Netherlands. Haemophilus influenzae strains (n = 316) isolated from cerebrospinal fluid (CSF), 1125 meningococcal strains isolated from blood or CSF and 398 pneumococcal strains isolated from CSF in 1993 and 1994 were tested by the Etest for susceptibility to commonly prescribed antibiotics for the treatment of community-acquired meningitis. In H. influenzae strains ampicillin-resistance occurred in 7.0%, resistance to chloramphenicol in 2.2%, and resistance to both antibiotics in 0.9%. The prevalence of intermediate penicillin-resistance in meningococci was 3.3%. Resistance to rifampicin was rarely found (0.1%). Intermediate penicillin-resistance in pneumococci was found in only 0.5% of isolates. All 1839 isolates were susceptible to ceftriaxone. Based on these results, we conclude that empirical therapy of childhood community-acquired bacterial meningitis with amoxycillin and chloramphenicol is no longer justified in children who have not been vaccinated against H. influenzae type b. In vaccinated or older children and adults, amoxycillin is a rational choice for empirical treatment of meningitis. The prophylactic use of rifampicin in contacts of patients with meningococcal disease is still applicable.
从细菌性脑膜炎患者中频繁分离出的病原体的抗菌耐药性不断增加,这构成了开展一项监测研究以确定荷兰耐药性流行情况的依据。采用Etest法对1993年和1994年从脑脊液(CSF)中分离出的316株流感嗜血杆菌、从血液或CSF中分离出的1125株脑膜炎球菌以及从CSF中分离出的398株肺炎球菌进行检测,以确定它们对常用于治疗社区获得性脑膜炎的抗生素的敏感性。在流感嗜血杆菌菌株中,氨苄西林耐药率为7.0%,氯霉素耐药率为2.2%,对两种抗生素均耐药的比例为0.9%。脑膜炎球菌对青霉素的中介耐药率为3.3%。对利福平的耐药情况很少见(0.1%)。肺炎球菌中仅0.5%的分离株对青霉素呈中介耐药。所有1839株分离株对头孢曲松均敏感。基于这些结果,我们得出结论,对于未接种b型流感嗜血杆菌疫苗的儿童,不再有理由使用阿莫西林和氯霉素对社区获得性细菌性脑膜炎进行经验性治疗。对于接种过疫苗的儿童或年龄较大的儿童及成人,阿莫西林是脑膜炎经验性治疗的合理选择。利福平在脑膜炎球菌病患者接触者中的预防性使用仍然适用。